Institutional Confidence in Sanofi Strengthens as Major Funds Increase Stakes

Major funds boost Sanofi holdings as analysts see 16% upside. The pharma giant nears a 31-year dividend growth streak, supported by strong cash flow from Dupixent.

Significant buying activity from prominent investment firms has underscored sustained institutional demand for Sanofi within the European pharmaceutical landscape. Recent regulatory filings reveal that several fund managers have substantially increased their holdings in the French healthcare giant. In a particularly notable move, Salomon & Ludwin LLC boosted its position by over 1,000 percent. Separately, the Aberdeen Group expanded its stake by 22.7 percent, bringing its total holding to 467,241 shares with an approximate market value of $22.6 million. Collectively, institutional investors and hedge funds now control close to 14 percent of the company's shares.

Analyst Consensus Points to Notable Upside

Market sentiment among research analysts remains decidedly positive. Out of 23 analysts covering the stock, 14 currently advocate a "buy" rating, with not a single "sell" recommendation in sight. The consensus 12-month price target stands at €96.10. Based on a recent share price near €82.58, this implies a potential upside of roughly 16 percent. The stock's price-to-earnings (P/E) ratio, sitting just below 10, is generally viewed as moderate relative to the broader healthcare sector.

The next significant catalyst for the share price is scheduled for April 23, 2026, when Sanofi reports its first-quarter financial results. This event will be accompanied by the ongoing support of a share buyback program, authorized for up to €1 billion in 2026.

A Dividend Track Record Approaching a Historic Milestone

A key pillar of Sanofi's investment appeal is its reliable shareholder returns. The board has proposed a dividend of €4.12 per share for 2025. If approved at the Annual Shareholders' Meeting on April 29, 2026, this increase would extend the company's streak of consecutive annual dividend raises to an impressive 31 years. At a current share price of approximately €83.50, this distribution offers a forward yield of nearly 5 percent. The ex-dividend date is set for May 5, with payment following two days later.

This financial consistency is underpinned by robust cash flow generation, primarily driven by the blockbuster drug Dupixent, coupled with a promising pipeline in immunology. Recent developmental milestones reinforce this strength: Rezurock secured EU approval for treating chronic graft-versus-host disease, and Phase 3 trial data for Amlitelimab showed positive outcomes in treating atopic dermatitis.